Ontology highlight
ABSTRACT: Background
Up to 70% of suspected Lynch syndrome patients harboring MMR deficient tumors lack identifiable germline pathogenic variants in MMR genes, being referred to as Lynch-like syndrome (LLS). Previous studies have reported biallelic somatic MMR inactivation in a variable range of LLS-associated tumors. Moreover, translating tumor testing results into patient management remains controversial. Our aim is to assess the challenges associated with the implementation of tumoral MMR gene testing in routine workflows.Methods
Here, we present the clinical characterization of 229 LLS patients. MMR gene testing was performed in 39 available tumors, and results were analyzed using two variant allele frequency (VAF) thresholds (≥5% and ≥10%).Results and discussion
More biallelic somatic events were identified at VAF ≥ 5% than ≥10% (35.9% vs. 25.6%), although the rate of nonconcordant results regarding immunohistochemical pattern increased (30.8% vs. 20.5%). Interpretation difficulties question the current utility of the identification of MMR somatic hits in the diagnostic algorithm of suspected LS cases.
SUBMITTER: Rofes P
PROVIDER: S-EPMC10983805 | biostudies-literature | 2024 Apr
REPOSITORIES: biostudies-literature
Rofes Paula P Dueñas Núria N Del Valle Jesús J Navarro Matilde M Balmaña Judith J Ramón Y Cajal Teresa T Tuset Noemí N Castillo Carmen C González Sara S Brunet Joan J Capellá Gabriel G Lázaro Conxi C Pineda Marta M
Cancer medicine 20240401 7
<h4>Background</h4>Up to 70% of suspected Lynch syndrome patients harboring MMR deficient tumors lack identifiable germline pathogenic variants in MMR genes, being referred to as Lynch-like syndrome (LLS). Previous studies have reported biallelic somatic MMR inactivation in a variable range of LLS-associated tumors. Moreover, translating tumor testing results into patient management remains controversial. Our aim is to assess the challenges associated with the implementation of tumoral MMR gene ...[more]